Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study

Raja Mudad, Maggie Ramsey, Kevin Kovitz, Tyler J. Curiel, Renee Hartz, Lucien L. Nedzi, Roy S. Weiner, Ellen L. Zakris

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The optimal dose of weekly docetaxel in combination with cisplatin and concomitant thoracic radiation therapy (XRT) in patients with locally advanced non-small cell lung cancer (NSCLC) is not well defined. The purpose of this study was to define the maximal tolerated dose (MTD) of docetaxel in this combination. Eligible patients had unresectable stage IIIA or IIIB NSCLC without pleural effusion. Treatment consisted of cisplatin 25 mg/m2 plus docetaxel weekly and concomitant standard XRT for a total of 60 Gy at 200 cGy/fraction/day 5 times weekly for 6 weeks. The starting dose of docetaxel in the first cohort was 15 mg/m2/week. This dose was escalated by 5 mg/m2 per cohort of 3 patients. No intrapatient dose escalation was allowed. The doses of cisplatin and XRT were not escalated. A total of 23 patients were enrolled, and 19 patients were evaluable for analysis. The first cohort (docetaxel 15 mg/m2/week) completed treatment without any Grade 3 or 4 toxicities. The second cohort (docetaxel 20 mg/m2/week) was expanded to 6 patients because of Grade 3 cough observed in 1 patient. One of 5 patients experienced Grade 3 esophagitis at the docetaxel 25 mg/m2/week dose level. Dose limiting toxicity consisting of Grade 3 esophagitis was reached in 4 of 5 patients receiving docetaxel at 30 mg/m2/week. This study determined the MTD of weekly docetaxel to be 25 mg/m2 when combined with cisplatin 25 mg/m2 and radiation therapy for locally advanced NSCLC. Further evaluation of this regimen in a phase II trial is underway.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalLung Cancer
Volume39
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Radiotherapy
Maximum Tolerated Dose
Esophagitis
Pleural Effusion
Cough

Keywords

  • Chemotherapy
  • Combined modality therapy
  • Lung cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer : A dose finding study. / Mudad, Raja; Ramsey, Maggie; Kovitz, Kevin; Curiel, Tyler J.; Hartz, Renee; Nedzi, Lucien L.; Weiner, Roy S.; Zakris, Ellen L.

In: Lung Cancer, Vol. 39, No. 2, 01.02.2003, p. 173-177.

Research output: Contribution to journalArticle

Mudad, Raja ; Ramsey, Maggie ; Kovitz, Kevin ; Curiel, Tyler J. ; Hartz, Renee ; Nedzi, Lucien L. ; Weiner, Roy S. ; Zakris, Ellen L. / Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer : A dose finding study. In: Lung Cancer. 2003 ; Vol. 39, No. 2. pp. 173-177.
@article{c73c3f21e89c49b595c5702681932c5e,
title = "Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study",
abstract = "The optimal dose of weekly docetaxel in combination with cisplatin and concomitant thoracic radiation therapy (XRT) in patients with locally advanced non-small cell lung cancer (NSCLC) is not well defined. The purpose of this study was to define the maximal tolerated dose (MTD) of docetaxel in this combination. Eligible patients had unresectable stage IIIA or IIIB NSCLC without pleural effusion. Treatment consisted of cisplatin 25 mg/m2 plus docetaxel weekly and concomitant standard XRT for a total of 60 Gy at 200 cGy/fraction/day 5 times weekly for 6 weeks. The starting dose of docetaxel in the first cohort was 15 mg/m2/week. This dose was escalated by 5 mg/m2 per cohort of 3 patients. No intrapatient dose escalation was allowed. The doses of cisplatin and XRT were not escalated. A total of 23 patients were enrolled, and 19 patients were evaluable for analysis. The first cohort (docetaxel 15 mg/m2/week) completed treatment without any Grade 3 or 4 toxicities. The second cohort (docetaxel 20 mg/m2/week) was expanded to 6 patients because of Grade 3 cough observed in 1 patient. One of 5 patients experienced Grade 3 esophagitis at the docetaxel 25 mg/m2/week dose level. Dose limiting toxicity consisting of Grade 3 esophagitis was reached in 4 of 5 patients receiving docetaxel at 30 mg/m2/week. This study determined the MTD of weekly docetaxel to be 25 mg/m2 when combined with cisplatin 25 mg/m2 and radiation therapy for locally advanced NSCLC. Further evaluation of this regimen in a phase II trial is underway.",
keywords = "Chemotherapy, Combined modality therapy, Lung cancer, Radiation therapy",
author = "Raja Mudad and Maggie Ramsey and Kevin Kovitz and Curiel, {Tyler J.} and Renee Hartz and Nedzi, {Lucien L.} and Weiner, {Roy S.} and Zakris, {Ellen L.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0169-5002(02)00448-8",
language = "English (US)",
volume = "39",
pages = "173--177",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer

T2 - A dose finding study

AU - Mudad, Raja

AU - Ramsey, Maggie

AU - Kovitz, Kevin

AU - Curiel, Tyler J.

AU - Hartz, Renee

AU - Nedzi, Lucien L.

AU - Weiner, Roy S.

AU - Zakris, Ellen L.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The optimal dose of weekly docetaxel in combination with cisplatin and concomitant thoracic radiation therapy (XRT) in patients with locally advanced non-small cell lung cancer (NSCLC) is not well defined. The purpose of this study was to define the maximal tolerated dose (MTD) of docetaxel in this combination. Eligible patients had unresectable stage IIIA or IIIB NSCLC without pleural effusion. Treatment consisted of cisplatin 25 mg/m2 plus docetaxel weekly and concomitant standard XRT for a total of 60 Gy at 200 cGy/fraction/day 5 times weekly for 6 weeks. The starting dose of docetaxel in the first cohort was 15 mg/m2/week. This dose was escalated by 5 mg/m2 per cohort of 3 patients. No intrapatient dose escalation was allowed. The doses of cisplatin and XRT were not escalated. A total of 23 patients were enrolled, and 19 patients were evaluable for analysis. The first cohort (docetaxel 15 mg/m2/week) completed treatment without any Grade 3 or 4 toxicities. The second cohort (docetaxel 20 mg/m2/week) was expanded to 6 patients because of Grade 3 cough observed in 1 patient. One of 5 patients experienced Grade 3 esophagitis at the docetaxel 25 mg/m2/week dose level. Dose limiting toxicity consisting of Grade 3 esophagitis was reached in 4 of 5 patients receiving docetaxel at 30 mg/m2/week. This study determined the MTD of weekly docetaxel to be 25 mg/m2 when combined with cisplatin 25 mg/m2 and radiation therapy for locally advanced NSCLC. Further evaluation of this regimen in a phase II trial is underway.

AB - The optimal dose of weekly docetaxel in combination with cisplatin and concomitant thoracic radiation therapy (XRT) in patients with locally advanced non-small cell lung cancer (NSCLC) is not well defined. The purpose of this study was to define the maximal tolerated dose (MTD) of docetaxel in this combination. Eligible patients had unresectable stage IIIA or IIIB NSCLC without pleural effusion. Treatment consisted of cisplatin 25 mg/m2 plus docetaxel weekly and concomitant standard XRT for a total of 60 Gy at 200 cGy/fraction/day 5 times weekly for 6 weeks. The starting dose of docetaxel in the first cohort was 15 mg/m2/week. This dose was escalated by 5 mg/m2 per cohort of 3 patients. No intrapatient dose escalation was allowed. The doses of cisplatin and XRT were not escalated. A total of 23 patients were enrolled, and 19 patients were evaluable for analysis. The first cohort (docetaxel 15 mg/m2/week) completed treatment without any Grade 3 or 4 toxicities. The second cohort (docetaxel 20 mg/m2/week) was expanded to 6 patients because of Grade 3 cough observed in 1 patient. One of 5 patients experienced Grade 3 esophagitis at the docetaxel 25 mg/m2/week dose level. Dose limiting toxicity consisting of Grade 3 esophagitis was reached in 4 of 5 patients receiving docetaxel at 30 mg/m2/week. This study determined the MTD of weekly docetaxel to be 25 mg/m2 when combined with cisplatin 25 mg/m2 and radiation therapy for locally advanced NSCLC. Further evaluation of this regimen in a phase II trial is underway.

KW - Chemotherapy

KW - Combined modality therapy

KW - Lung cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0037316545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037316545&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(02)00448-8

DO - 10.1016/S0169-5002(02)00448-8

M3 - Article

C2 - 12581570

AN - SCOPUS:0037316545

VL - 39

SP - 173

EP - 177

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -